Randomized non-comparative phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma unable for cisplatin-based chemotherapy. NIVOTAX TTCC study.

Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) who are ineligible for cisplatin have limited treatment options, and the role of chemoimmunotherapy in this population remains unexplored. NIVOTAX was a randomized, non-comparative, multicenter, phase II trial ev...

Descripción completa

Detalles Bibliográficos

Publicado en:	European Journal of Cancer Vol. 241
Autores principales:	Docampo, Lara Iglesias, Basté, Neus, Oliva, Marc, Carral, Alberto, Pérez Segura, Pedro, Medina-Colmenero, Ana, Cirauqui, Beatriz, Arrazubi, Virginia, Martínez Trufero, Javier, Gutiérrez Calderón, Vanesa, García Castaño, Almudena, Rubió-Casadevall, Jordi, del Barco, Edel, Basterretxea, Laura, Bruixola, Gema, Cabellos, Ruth Álvarez, Flor, María José, Braña, Irene, Caballero, Javier, Martínez, Joaquina
Formato:	research randomized controlled trial Journal Article
Publicado:	Pergamon Press - An Imprint of Elsevier Science Jun2026
Acceso en línea:	Ver este registro en EBSCOhost